- Home
- PHIO vs CHRO Comparison
PHIO vs CHRO Comparison
Compare PHIO & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHIO
- CHRO
- Stock Information
- Founded
- PHIO 2011
- CHRO 2002
- Country
- PHIO United States
- CHRO United States
- Employees
- PHIO N/A
- CHRO N/A
- Industry
- PHIO Biotechnology: Pharmaceutical Preparations
- CHRO
- Sector
- PHIO Health Care
- CHRO
- Exchange
- PHIO Nasdaq
- CHRO Nasdaq
- Market Cap
- PHIO 3.4M
- CHRO 3.8M
- IPO Year
- PHIO N/A
- CHRO 2024
- Fundamental
- Price
- PHIO $2.77
- CHRO $1.90
- Analyst Decision
- PHIO Strong Buy
- CHRO Strong Buy
- Analyst Count
- PHIO 1
- CHRO 1
- Target Price
- PHIO $36.00
- CHRO N/A
- AVG Volume (30 Days)
- PHIO 18.5M
- CHRO 855.2K
- Earning Date
- PHIO 11-14-2024
- CHRO 02-20-2025
- Dividend Yield
- PHIO N/A
- CHRO N/A
- EPS Growth
- PHIO N/A
- CHRO N/A
- EPS
- PHIO N/A
- CHRO N/A
- Revenue
- PHIO N/A
- CHRO N/A
- Revenue This Year
- PHIO N/A
- CHRO N/A
- Revenue Next Year
- PHIO N/A
- CHRO N/A
- P/E Ratio
- PHIO N/A
- CHRO N/A
- Revenue Growth
- PHIO N/A
- CHRO N/A
- 52 Week Low
- PHIO $1.53
- CHRO $0.45
- 52 Week High
- PHIO $10.35
- CHRO $6.00
- Technical
- Relative Strength Index (RSI)
- PHIO 50.99
- CHRO 86.63
- Support Level
- PHIO $2.41
- CHRO $0.81
- Resistance Level
- PHIO $4.53
- CHRO $1.10
- Average True Range (ATR)
- PHIO 0.83
- CHRO 0.26
- MACD
- PHIO 0.12
- CHRO 0.08
- Stochastic Oscillator
- PHIO 14.18
- CHRO 70.64
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.